Suppliers and packagers for DOVATO

DOVATO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13)	2019-04-08
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-33	1 BLISTER PACK in 1 CARTON (49702-246-33) / 30 TABLET, FILM COATED in 1 BLISTER PACK	2019-04-08
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-62	1 BLISTER PACK in 1 CARTON (49702-246-62) / 14 TABLET, FILM COATED in 1 BLISTER PACK	2019-04-08

Dovato Supplier Landscape

Last updated: February 19, 2026

Dovato, a combination antiretroviral therapy for HIV-1 infection, relies on a global network of specialized suppliers for its active pharmaceutical ingredients (APIs) and key excipients. The patent landscape for Dovato (dolutegravir and lamivudine) is managed by ViiV Healthcare, a joint venture of GSK, Pfizer, and Shionogi. While the primary manufacturing of the finished drug product is consolidated, the sourcing of its constituent components involves a diverse set of chemical manufacturers and service providers.

What are the primary active pharmaceutical ingredients (APIs) in Dovato?

Dovato contains two distinct APIs:

• Dolutegravir: A potent integrase strand transfer inhibitor (INSTI).
• Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI).

Each API requires distinct synthetic pathways and specialized manufacturing capabilities.

Who are the key suppliers of Dolutegravir API?

The synthesis of dolutegravir is a complex multi-step process. Key suppliers are often found in regions with established fine chemical and API manufacturing infrastructure. While ViiV Healthcare maintains proprietary control over the final API production, it leverages contract manufacturing organizations (CMOs) for various stages of the synthesis.

• Lonza Group AG: A Swiss multinational manufacturing company, Lonza is a significant player in API production, including complex molecules like dolutegravir. Their capabilities span custom synthesis and large-scale API manufacturing. Lonza has a long-standing relationship with GSK, the lead partner in ViiV Healthcare. [1]
• Divi's Laboratories Limited: An Indian pharmaceutical company known for its large-scale API manufacturing. Divi's has a strong track record in producing complex APIs and has been identified as a supplier for various GSK products. [2]
• Other Contract Manufacturers: ViiV Healthcare may engage a broader network of CMOs globally, depending on specific manufacturing intermediates and capacity requirements. These can include companies in China, India, and Europe specializing in complex organic synthesis. Identifying these specific entities can be challenging due to the proprietary nature of supply chain agreements.

The sourcing strategy for dolutegravir API likely involves multiple qualified suppliers to ensure supply chain resilience and manage cost.

What are the primary suppliers of Lamivudine API?

Lamivudine is a more established API, with a broader manufacturing base compared to dolutegravir.

• GSK (GlaxoSmithKline): As a founding partner of ViiV Healthcare, GSK likely retains significant internal API manufacturing capacity for lamivudine. This vertical integration can provide cost advantages and supply chain control. [3]
• Major Generic API Manufacturers: Several large-scale API manufacturers globally produce lamivudine, often supplying to both innovator and generic drug manufacturers. These include:
  • Teva Pharmaceutical Industries Ltd.: A global pharmaceutical company with extensive API manufacturing capabilities.
  • Mylan N.V. (now Viatris): Another significant producer of generic APIs.
  • Indian API Manufacturers: Companies such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries are prominent producers of lamivudine API. [4]

ViiV Healthcare’s choice of lamivudine suppliers would consider factors such as regulatory compliance, quality assurance, cost, and security of supply.

What are the key excipients used in Dovato and their suppliers?

Beyond the APIs, Dovato formulations require various inactive ingredients (excipients) that provide stability, facilitate tablet formation, and aid in drug release. The specific excipients and their suppliers are critical for product quality and performance.

Table 1: Key Excipients in Dovato (Typical Formulation)

Excipient Category	Example Component	Function in Formulation	Potential Supplier Type
Diluent	Microcrystalline Cellulose	Provides bulk and compressibility	FMC Corporation, JRS Pharma, DuPont (now IFF)
Binder	Povidone (PVP)	Aids in granule formation and tablet cohesion	Ashland, BASF, Sigma-Aldrich
Disintegrant	Croscarmellose Sodium	Promotes tablet breakdown for drug release	JRS Pharma, Ashland, Croda International
Lubricant	Magnesium Stearate	Prevents tablet sticking to manufacturing dies	Godrej Industries, Associated Chemical Enterprises
Coating Agent	Hypromellose (HPMC)	Film coating for tablet protection and appearance	Shin-Etsu Chemical, Ashland, DuPont (now IFF)
Plasticizer	Triacetin	Improves flexibility of the film coating	Eastman Chemical Company, BASF
Opacifier	Titanium Dioxide	Provides opacity and color to the coating	Chemours, Tronox, Venator Materials

Supplier Landscape for Excipients:

The excipient market is characterized by a number of large, multinational chemical companies that specialize in pharmaceutical-grade ingredients.

• Lubricants (e.g., Magnesium Stearate): Sourced from companies with strong expertise in fatty acid derivatives. Global players include Godrej Industries (India) and Associated Chemical Enterprises.
• Binders and Coating Agents (e.g., Povidone, HPMC): These are often supplied by major chemical and specialty ingredient companies. Ashland, BASF, and DuPont (now part of IFF) are prominent suppliers. Shin-Etsu Chemical is a key producer of HPMC.
• Disintegrants (e.g., Croscarmellose Sodium): Specialized cellulose derivatives. JRS Pharma and Ashland are significant providers.
• Diluents (e.g., Microcrystalline Cellulose): Widely produced by companies focused on cellulose derivatives for pharmaceutical applications. FMC Corporation and JRS Pharma are leading names.
• Coating Materials: Companies that produce polymers for film coatings are critical. This includes manufacturers of HPMC and related polymers.

ViiV Healthcare's procurement strategy for excipients focuses on suppliers that meet stringent Good Manufacturing Practice (GMP) standards and possess robust quality management systems. The selection process involves rigorous qualification and audits to ensure batch-to-batch consistency and compliance with regulatory requirements in all target markets.

What is the role of Contract Manufacturing Organizations (CMOs) in Dovato's supply chain?

CMOs play a pivotal role in the pharmaceutical supply chain, particularly for complex molecules like dolutegravir. ViiV Healthcare likely utilizes CMOs for:

• Intermediate Synthesis: Producing key chemical building blocks for dolutegravir and, potentially, lamivudine.
• API Manufacturing: Outsourcing the final steps of API synthesis or the entire API production for one or both components.
• Finished Dosage Form (FDF) Manufacturing: While ViiV may have internal FDF manufacturing capabilities, outsourcing to specialized CMOs can provide flexibility, capacity expansion, and geographic diversification.

Key Considerations for CMO Selection:

• Regulatory Compliance: Experience with FDA, EMA, and other global regulatory bodies is essential.
• Technical Expertise: Capabilities in complex organic synthesis, analytical testing, and process optimization.
• Quality Systems: Robust quality management systems (QMS) and a strong audit history.
• Capacity and Scalability: Ability to meet ViiV's current and future demand.
• Supply Chain Security: Redundancy in raw material sourcing and manufacturing sites.
• Intellectual Property Protection: Strict adherence to confidentiality and IP safeguarding.

Companies like Lonza, Catalent, and Thermo Fisher Scientific (through its Patheon brand) are examples of large CMOs with the breadth of services and regulatory track record to support complex drug products like Dovato.

How do patents influence the supplier landscape for Dovato?

The patent status of dolutegravir and lamivudine directly shapes the supplier landscape.

• Dolutegravir Patents: ViiV Healthcare holds patents on dolutegravir. These patents, and their expiry dates, dictate when generic manufacturers can enter the market and, consequently, when a broader range of API suppliers might become available for generic versions of dolutegravir. The primary patents for dolutegravir are expected to expire in the mid-to-late 2030s in major markets, though specific patent expiry dates can vary by country and may be subject to extensions or challenges. [5]
• Lamivudine Patents: Lamivudine is an older drug, and its primary patents have long expired. This has led to a mature market with multiple generic API suppliers. ViiV Healthcare, however, still controls the patent for the fixed-dose combination formulation of dolutegravir and lamivudine under the brand name Dovato. [6]
• Formulation Patents: Patents covering the specific tablet composition, manufacturing process, or extended-release mechanisms of Dovato can also influence the supply chain, particularly for any specialized excipients or manufacturing technologies required.

As patents expire, ViiV Healthcare may license its technology or enter into agreements with generic manufacturers, which can broaden the base of API and excipient suppliers involved in the production of the molecule.

What are the regulatory considerations for Dovato suppliers?

Suppliers of APIs and excipients for pharmaceuticals like Dovato must adhere to strict regulatory requirements.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP guidelines established by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This ensures product quality, safety, and efficacy.
• Drug Master Files (DMFs): API suppliers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API. ViiV Healthcare would cross-reference these DMFs in its drug applications.
• Quality Agreements: Formal quality agreements are established between ViiV Healthcare and its suppliers. These agreements define specific quality standards, testing protocols, change control procedures, and audit rights.
• Supply Chain Audits: ViiV Healthcare conducts regular audits of its suppliers to ensure ongoing compliance with regulatory standards and internal quality policies.
• Country-Specific Regulations: Suppliers must comply with the specific regulatory requirements of each country where Dovato will be marketed, including registration, import/export controls, and labeling.

The rigorous regulatory environment necessitates that suppliers invest heavily in quality assurance and regulatory affairs expertise.

Key Takeaways

• Dovato's supply chain involves specialized manufacturers for its two APIs, dolutegravir and lamivudine, and a diverse range of global chemical companies for its excipients.
• Lonza Group and Divi's Laboratories are identified as potential significant suppliers for the complex dolutegravir API, while GSK and various large generic API manufacturers likely supply lamivudine.
• Excipient suppliers include major multinational corporations such as Ashland, BASF, FMC Corporation, and JRS Pharma, providing essential ingredients like microcrystalline cellulose, povidone, and magnesium stearate.
• Contract Manufacturing Organizations (CMOs) are integral to ViiV Healthcare's strategy for API synthesis and potentially finished drug product manufacturing, ensuring capacity, flexibility, and specialized capabilities.
• The patent lifecycle of dolutegravir is a critical factor influencing the future supplier landscape, with generics expected to broaden supplier options upon patent expiry in the mid-to-late 2030s.
• All suppliers must maintain stringent adherence to global GMP regulations, quality agreements, and rigorous audit protocols enforced by ViiV Healthcare and regulatory bodies.

FAQs

1. Can generic manufacturers produce Dovato currently? Generic manufacturers cannot produce Dovato in its fixed-dose combination formulation while ViiV Healthcare's formulation patents remain in effect. However, once patents for dolutegravir expire, generic versions of dolutegravir as a single agent may become available, potentially involving a broader set of API suppliers.

2. How does ViiV Healthcare ensure the quality of its suppliers? ViiV Healthcare employs a multi-faceted approach including rigorous supplier qualification processes, establishment of detailed quality agreements, and regular on-site audits to ensure compliance with GMP and other regulatory standards.

3. What is the typical lead time for sourcing specialized APIs like dolutegravir? Lead times for specialized APIs can range from several months to over a year, depending on the complexity of the synthesis, current market demand, and the supplier's existing production schedule and raw material availability.

4. Are there regional concentrations of Dovato suppliers? While API manufacturing for dolutegravir and lamivudine involves global players, significant concentrations of specialized chemical manufacturing capabilities exist in India, China, Europe, and North America, particularly for excipients and intermediate synthesis.

5. What happens if a key supplier for Dovato experiences a disruption? ViiV Healthcare mitigates supply chain risk by qualifying multiple suppliers for critical APIs and excipients and by maintaining robust inventory management and contingency planning.

Citations

[1] Lonza Group AG. (n.d.). API Manufacturing. Retrieved from https://www.lonza.com/ (Note: Specific project details are proprietary and not publicly disclosed by Lonza).

[2] Divi's Laboratories Limited. (n.d.). Products. Retrieved from https://www.divis.com/ (Note: Specific supply agreements are confidential).

[3] GlaxoSmithKline plc. (n.d.). Our medicines. Retrieved from https://www.gsk.com/ (Note: Internal manufacturing capabilities for established APIs are common but not always publicly detailed).

[4] Pharmaceutical industry reports and market analyses (e.g., Informa Pharma Intelligence, EvaluatePharma). (Various dates). (Note: Specific supplier lists are proprietary market data).

[5] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Note: Patent information is publicly searchable but complex and can involve multiple patents and extensions).

[6] ViiV Healthcare. (n.d.). Dovato Prescribing Information. Retrieved from https://www.viivhealthcare.com/ (Note: Prescribing information does not detail supplier information but confirms the product's components and indications).